特异性尘螨过敏原免疫疗法辅助信必可都保雾化吸入治疗中重度支气管哮喘的临床研究

摘要

目的：：探讨特异性尘螨过敏原免疫疗法辅助信必可都保(布地奈德福莫特罗粉吸入剂)雾化吸入治疗中重度支气管哮喘临床效果及安全性。方法：2012年5月—2013年1月选取本院中重度支气管哮喘患者130例，采用随机数字表法分为对照组和试验组，每组65例；其中对照组患者采用信必可都保雾化吸入治疗，试验组患者则在此基础上加用特异性尘螨过敏原免疫疗法；比较两组患者临床疗效，治疗前后肺部通气功能指标，哮喘症状评分、哮喘生活质量评分及治疗期间不良反应发生情况等。结果：试验组患者临床疗效显著优于对照组( P<0.05)；两组患者治疗后肺部通气功能指标水平、哮喘症状评分及哮喘生活质量评分较治疗前均显著改善，且试验组患者治疗后各项指标水平优于对照组( P<0.05)；两组患者治疗期间不良反应总发生率比较差异无统计学意义( P>0.05)。结论：特异性尘螨过敏原免疫疗法辅助信必可都保雾化吸入治疗中重度支气管哮喘可有效缓解症状体征，提高肺部通气功能和生活质量，且未增加不良反应发生风险。%Objective:To investigate clinical effects and safety of specific dust mite allergen immunotherapy combined with Symbicort Turbuhaler inhalation in treatment of bronchial asthma with medium type and severe type.Methods:130 patients with bronchial asthma with medium type and severe type were chosen and randomly divided into both group including control group ( 65 patients) with Symbicort Turbuhaler inhalation treatment and experiment group ( 65 patients) with specific dust mite allergen immunotherapy on the basis of control group;and the clinical efficacy, before and after treatment pulmonary ventilation function index, asthma symptom score, life quality score of asthma and adverse effects occurrence of both groups were compared.Results:The clinical efficacy of experiment group was significantly better than control group ( P<0. 05 ) . The after treatment pulmonary ventilation function index, asthma symptom score, life quality score of asthma of both groups was significantly better than before treatment ( P<0. 05 ) . The indexes above of experiment group was significantly better than control group( P<0.05) . There was no significant difference in adverse effects occurrence between 2 groups ( P>0.05).Conclusion:Specific dust mite allergen immunotherapy combined with Symbicort Turbuhaler inhalation in treatment of bronchial asthma with medium type and severe type can efficiently relieve clinical symptoms and signs,higher pulmonary ventilation function and life quality and have no increased risk of adverse effects.